Literature DB >> 17276891

Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis.

Laura Camacho-Barquero1, Isabel Villegas, Juan Manuel Sánchez-Calvo, Elena Talero, Susana Sánchez-Fidalgo, Virginia Motilva, Catalina Alarcón de la Lastra.   

Abstract

Ulcerative colitis (UC) is a nonspecific inflammatory disorder characterized by oxidative and nitrosative stress, leucocyte infiltration and up-regulation of pro-inflammatory cytokines. Mitogen-activated protein kinases (MAPKs), such as the p38 and the c-Jun N-terminal kinase (JNK) modulate the transcription of many genes involved in the inflammatory process. Curcumin is a polyphenol derived from Curcuma longa, which is known to have anti-inflammatory activity. The aim of this study was to study the effects and mechanisms of action of curcumin, on chronic colitis in rats. Inflammation response was assessed by histology and myeloperoxidase activity (MPO). We determined the production of Th1 and Th2 cytokines and nitrites in colon mucosa, as well as the expression of inducible nitric oxide synthase (iNOS), cyclo-oxygenase(COX)-1 and-2 by western blotting and inmmunohistochemistry. Finally, we studied the involvement of MAPKs signaling in the protective effect of curcumin in chronic colonic inflammation. Curcumin (50-100 mg/kg/day) were administered by oral gavage 24 h after trinitrobenzensulfonic acid (TNBS) instillation, and daily during 2 weeks before sacrifice. Curcumin significantly attenuated the damage and caused substantial reductions of the rise in MPO activity and tumour necrosis factor alpha (TNF)-alpha. Also curcumine was able to reduce nitrites colonic levels and induced down-regulation of COX-2 and iNOS expression, and a reduction in the activation of p38 MAPK; however, no changes in the activation of JNK could be observed. In conclusion, we suggest that inhibition of p38 MAPK signaling by curcumin could explain the reduced COX-2 and iNOS immunosignals and the nitrite production in colonic mucosa reducing the development of chronic experimental colitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17276891     DOI: 10.1016/j.intimp.2006.11.006

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  73 in total

Review 1.  Bone, inflammation, and inflammatory bowel disease.

Authors:  Manasi Agrawal; Shitij Arora; Jianjun Li; Rabin Rahmani; Li Sun; Adam F Steinlauf; Jeffrey I Mechanick; Mone Zaidi
Journal:  Curr Osteoporos Rep       Date:  2011-12       Impact factor: 5.096

2.  Curcumin inhibits epigen and amphiregulin upregulated by 2,4,6-trinitrochlorobenzene associated with attenuation of skin swelling.

Authors:  Hiroyasu Sakai; Ken Sato; Fumiaki Sato; Yuki Kai; Kazutaka Mandokoro; Kenjiro Matsumoto; Shinichi Kato; Tetsuro Yumoto; Minoru Narita; Yoshihiko Chiba
Journal:  Inflamm Res       Date:  2017-04-12       Impact factor: 4.575

3.  Effects of curcumin and Ginkgo biloba on matrix metalloproteinases gene expression and other biomarkers of inflammatory bowel disease.

Authors:  Tarek Kamal Motawi; Sherine Maher Rizk; Ahmed Hassan Shehata
Journal:  J Physiol Biochem       Date:  2012-04-26       Impact factor: 4.158

4.  The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate.

Authors:  Heba S Aboul Ezz; Yasser A Khadrawy; Neveen A Noor
Journal:  Neurochem Res       Date:  2011-07-13       Impact factor: 3.996

Review 5.  A review on the role of nutraceuticals as simple as se(2+) to complex organic molecules such as glycyrrhizin that prevent as well as cure diseases.

Authors:  Regi Jose; G R Sajitha; K T Augusti
Journal:  Indian J Clin Biochem       Date:  2013-07-23

Review 6.  Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Authors:  Diego Currò; Gianluca Ianiro; Silvia Pecere; Stefano Bibbò; Giovanni Cammarota
Journal:  Br J Pharmacol       Date:  2016-10-25       Impact factor: 8.739

Review 7.  Targeting Nuclear Factor-Kappa B Signaling Pathway by Curcumin: Implications for the Treatment of Multiple Sclerosis.

Authors:  Meysam Gachpazan; Sadra Habbibirad; Hoda Kashani; Tannaz Jamialahmadi; Hamid Reza Rahimi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  The Use of Curcumin for the Treatment of Renal Disorders: A Systematic Review of Randomized Controlled Trials.

Authors:  Mohammad Bagherniya; Davood Soleimani; Mohammad Hossein Rouhani; Gholamreza Askari; Thozhukat Sathyapalan; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 9.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

10.  Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD.

Authors:  Victoria Y L Ung; Rae R Foshaug; Sarah M MacFarlane; Thomas A Churchill; Jason S G Doyle; Beate C Sydora; Richard N Fedorak
Journal:  Dig Dis Sci       Date:  2009-06-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.